Sanzhiji Completes RMB 330 Million Series B Financing Co-led by Matrix Partners China and CPE Yuanfeng to Advance 3D-Printed Drug Development

VCBeat (WeChat: vcbeat) has learned thatRecently, globally3DPrinted Drug Pioneer – Nanjing TRIASTEK Pharmaceutical Technology Co., Ltd. (hereinafter referred to as “TRIASTEK”) Completes3.3100 million yuanBround of financing. This round was led by Matrix Partners China,CPEYuanfeng jointly led the investment, with Shanghai Science and Technology Innovation Fund following up. Existing shareholders Morningside Venture Capital, Dalton Venture, and Yun Qi Partners continued to increase their stakes. China Renaissance served as the exclusive financial advisor for this round of financing. The funds from this round will accelerate the company's3DPrinted Drug Product Development and Business Expansion: Advancing TRIASTEK’s Vision to Launch a New Era of Global Intelligent Pharmaceutical Manufacturing.

Founded in 2015, TRIASTEK is the only 3D-printed pharmaceutical company in China, dedicated to building a novel 3D-printed drug technology platform. It has developed proprietary technologies covering the entire value chain, from dosage form design and digital development to intelligent manufacturing. Currently, as the first Chinese pharmaceutical company selected for the U.S. FDA’s Emerging Technology Program, TRIASTEK is participating in the formulation of industry standards for 3D-printed drugs under the United States Pharmacopeia (USP).

TRIASTEK’s core technology is the world’s first Melt Extrusion Deposition (MED®) 3D printing technology. This 3D printing technology, tailored for pharmaceutical manufacturing, offers exceptional versatility and has fundamentally disrupted traditional drug product development and pharmaceutical production methods. Leveraging this world-leading 3D-printed drug technology, TRIASTEK has pioneered a digital formulation development approach called “Formulation by Design (3DFbD®),” transforming the traditional, lengthy trial-and-error formulation development model into a designable and controllable digital process, thereby significantly enhancing the efficiency and success rate of new drug R&D. Notably, TRIASTEK’s production lines have achieved fully digitalized manufacturing and real-time quality monitoring, ensuring that every 3D-printed tablet produced is traceable, thus providing more advanced tools for pharmaceutical production management and regulatory compliance.

Triastek has established a robust 3D-printed drug delivery technology platform. By enabling programmed, precise control over drug release, the company precisely modulates pharmacokinetic profiles to develop 505(b)(2) products with greater clinical value. Its lead product, T19, received Investigational New Drug (IND) approval from the U.S. FDA in January 2021 for the treatment of rheumatoid arthritis and is poised to become the second 3D-printed pharmaceutical product approved globally. This product was submitted to China’s National Medical Products Administration (NMPA) in June of this year via the Class 2 improved new drug pathway. The company’s second product, T20, received positive feedback from the U.S. FDA on its Pre-IND (PIND) application in March of this year and is scheduled for IND submission by the end of the year. Over the next year, Triastek plans to submit PIND meeting requests to the FDA for three additional products.

In addition to developing its proprietary products, TRIASTEK is actively exploring various application scenarios for new technologies. The company collaborates with multiple multinational pharmaceutical enterprises to leverage MED 3D printing technology in addressing the poor druggability of new chemical entities due to low solubility, as well as in developing next-generation drug products that can extend the lifecycle of new chemical entities. In China, the company partners with Shanghai Huiyong Pharmaceutical (a subsidiary of Shanghai Pharmaceuticals Group), Shufang Pharma, and others, providing them with differentiated new drug products that possess strong market competitiveness.

Dr. Cheng Senping, Co-founder and CEO of TRIASTEKstated: “We extend our gratitude to Matrix Partners China, CPE Yuanfeng, the Shanghai Science and Technology Innovation Fund, and the company’s existing shareholders for their support of TRIASTEK, as well as to China Renaissance for its assistance. Making medicines of higher quality, advancing the pharmaceutical industry, and improving human health are the goals TRIASTEK relentlessly pursues. We will fully leverage the advantages of 3D-printed medicines as a digital manufacturing technology and harness emerging technologies such as artificial intelligence to promote the digitalization and intelligent transformation of drug development and production, thereby accumulating experience and setting benchmarks for the modernization of the global pharmaceutical industry.”

Dr. Yu Zhiyun, Partner at Matrix Partners ChinaIt stated: “TRIASTEK’s groundbreaking 3D-printed drug technology platform can accommodate nearly all types of target drug release profiles. As the first Chinese company selected for the FDA’s Emerging Technology Program, TRIASTEK has established high technological barriers and accumulated extensive expertise across all stages of pharmaceutical formulation. It has achieved a closed-loop process encompassing target release profile design, formulation structure and component design, establishment of formulation models, prototype printing verification, and large-scale manufacturing, which holds breakthrough significance for new drug development. We are highly optimistic about TRIASTEK’s future ability to leverage its technology platform to deliver a continuous pipeline of innovative drugs addressing unmet clinical needs for patients.”

Ms. Wu Jing, Executive Director of CPE Yuanfeng“It stated: ‘TRIASTEK has assembled a multidisciplinary team spanning pharmaceuticals, equipment, and materials. Through years of continuous R&D and innovation, it has developed the world’s first MED technology, establishing a digital formulation technology platform that covers the entire value chain from drug delivery and product development to intelligent manufacturing, along with a comprehensive patent portfolio. CPE Yuanfeng has consistently focused on emerging technologies in drug development and firmly believes that TRIASTEK will become a globally influential 3D-printed drug technology platform, leading industry development and contributing to the accelerated digitalization and intelligent transformation of the traditional pharmaceutical sector.’”

Dr. Yuan Zhide, Executive Vice President of Shanghai Science and Technology Innovation Fundstated: “First, congratulations to TRIASTEK on completing its Series B financing. The TRIASTEK team possesses extensive experience in pharmaceutics and manufacturing, along with strong interdisciplinary execution capabilities. Through years of relentless effort, the company has developed the world’s first 3D printing technology for programmable, precision-controlled drug release. By combining this technology with unique three-dimensional structural designs, the company can develop pharmaceutical products with enhanced safety and efficacy. Furthermore, this technology improves the development efficiency of innovative drugs, enabling faster delivery of more effective treatments to patients. We have full confidence in the company’s technology and team capabilities, and look forward to seeing its technology more widely applied in pharmaceutical R&D and production.”

Xie Yijing, Managing Director and Head of the Healthcare & Life Sciences Group at China Renaissance“We are honored to assist TRIASTEK in closing this round of financing. 3D-printed drug technology is transformative for the pharmaceutical industry and represents the future direction of pharmaceutical manufacturing. We look forward to TRIASTEK, as a leader in this field, ushering in a new chapter of innovative development for the global pharmaceutical industry.”

Matrix Partners China, established in 2008, is a leading venture capital firm in China. Over the past decade since its inception, it has remained deeply rooted in the local market, steadfastly investing in Chinese entrepreneurs. Matrix Partners China has invested in more than 700 companies to date. Notable portfolio companies include Didi Chuxing, XPeng Motors, Li Auto, Futu Holdings, Chehaoduo Group, Youzan, Ronbay Technology, XGIMI Technology, Momo, Ele.me, Peijia Medical, Kymed Diagnostics, Genor Biopharma, Career International, LexinFintech, So-Young, Yuanfudao, PingCAP, Zihai Guo, Jian Ai, i-Space, Taimei Medical Technology, and Drug Research Club.

CPE Yuanfeng is an asset management institution with a global perspective and extensive experience in China. Committed to a long-term vision and value investment strategy, the firm focuses on providing innovative investment solutions to leading enterprises in four key sectors: Healthcare & Health, Consumer & Internet, Technology & Industry, and Software & Enterprise Services. Currently, the funds under its management have earned the trust and support of over 200 institutional investors both domestically and internationally, with cumulative assets under management exceeding RMB 100 billion. Over the past decade, the company’s core team has invested in more than 200 enterprises, accumulating profound industry insights and an extensive resource network. Leveraging a robust investment research system and professional post-investment management capabilities, CPE Yuanfeng is dedicated to building long-term partnerships with its portfolio companies. It aims to support their sustainable development, deliver substantial returns to investors, drive overall industry advancement, and create positive social impact.

Established in 2017, the Shanghai Science and Technology Innovation Fund counts Shanghai International Group, Guosheng Group, Shanghai International Port Group, Shanghai Trust, Guotai Junan Securities, and Zhangjiang High-Tech among its cornerstone investors. With a Phase I assets under management (AUM) of RMB 6.52 billion, the fund focuses primarily on strategic emerging industries such as information technology, biomedicine, advanced manufacturing, and environmental protection and new energy. By forging deep collaborations with leading sub-fund managers in the market and leveraging the ecosystem advantages of a fund-of-funds structure, the Shanghai Science and Technology Innovation Fund is dedicated to nurturing start-ups that align with national strategies, possess technological leadership and originality, demonstrate significant import substitution potential within the dual-circulation framework, and exhibit unicorn potential. These efforts aim to accelerate Shanghai’s development into a globally influential science and technology innovation hub.

Morningside Ventures, a member of the Morningside Group, conducts high-tech venture capital investments globally. Since its establishment in 1986, Morningside Ventures has been dedicated to supporting biotechnology companies in their startup and growth stages, with investments spanning new drug development, clinical diagnostics, medical devices, healthcare services, and digital health. The firm boasts an excellent investment management team, most of whose members possess experience in corporate operations and entrepreneurship, and have a deep understanding of the frontiers of life sciences, the healthcare industry, and the entrepreneurial and investment environments across different regions.

Dalton Venture focuses on early-stage investments and industrial M&A within the healthcare sector, with investment areas spanning medical devices, healthcare services, biopharmaceuticals, and healthcare informatics. The core team members all hail from the healthcare industry, bringing extensive experience in corporate operations management, investment, and mergers and acquisitions. They possess both entrepreneurial experience in incubating early-stage enterprises and expertise in managing publicly listed companies with market capitalizations reaching tens of billions. Dalton Venture has established a deep footprint in the field of medical innovation technologies. The Dalton Venture team is highly stable and has built a robust investment ecosystem. Leveraging profound industry experience and extensive, high-quality industry resources, the firm provides strong post-investment support, creating high-value returns for its partners.

Yun Qi Partners, established in 2014, has consistently focused on early-to-mid-stage investments in the To-B sector. Centered on leveraging technology to empower industrial upgrading, the firm has implemented a systematic investment strategy spanning industries such as enterprise SaaS, industrial digitalization, intelligent connected devices, and advanced manufacturing. Its portfolio includes over 100 outstanding startups, such as 360 DigiTech (NASDAQ: QFIN), Intco Medical (SZ: 300677), Yiqixie (acquired by Kuaishou), Kujiale, Baibu, PingCAP, Zilliz, Defeng Technology, IceKredit, XTransfer, WorldWide Logistics Group, TRIASTEK, Zhaogang.com, XiaoPangXiong, Sobot Technology, Xiaoyang Education, Keenon Robotics, Neolix, and e-Huan Dian.